Nucleotide analogs

Patent metadata

Field	Value
Publication number	US-9493493-B2
Application number	US-201514854897-A
Country	US
Kind code	B2
Filing date	Sep 15, 2015
Priority date	Sep 15, 2014
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

First claim

What is claimed is:

1. A compound selected from the group consisting of:

2. A compound selected from the group consisting of:

wherein
R M is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocyclyl)alkyl, hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, azido, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, mono-substituted amino group or a di-substituted amino group; and
the phenyl ring can be substituted by R M 1, 2 or 3 times;
or a pharmaceutically acceptable salt thereof.

3. A compound selected from the group consisting of:

wherein
R M is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocyclyl)alkyl, hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, azido, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, mono-substituted amino group or a di-substituted amino group; and
the phenyl ring can be substituted by R M 1, 2 or 3 times;
or a pharmaceutically acceptable salt thereof.

4. A compound selected from the group consisting of:

wherein
R M is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocyclyl)alkyl, hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, azido, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, mono-substituted amino group or a di-substituted amino group; and
the phenyl ring can be substituted by R M 1, 2 or 3 times;
or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition, comprising an effective amount of a compound of claim 1 , in a pharmaceutically acceptable carrier.

6. A pharmaceutical composition, comprising an effective amount of a compound of claim 2 , in a pharmaceutically acceptable carrier.

7. A pharmaceutical composition, comprising an effective amount of a compound of claim 3 , in a pharmaceutically acceptable carrier.

8. A pharmaceutical composition, comprising an effective amount of a compound of claim 4 , in a pharmaceutically acceptable carrier.

9. A method of treating a host infected with a human papillomavirus, comprising administering an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

10. A method of treating a host infected with a human papillomavirus, comprising administering an effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

11. A method of treating a host infected with a human papillomavirus, comprising administering an effective amount of a compound of claim 3 , or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

12. A method of treating a host infected with a human papillomavirus, comprising administering an effective amount of a compound of claim 4 , or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

13. The method of claim 9 , wherein the human papillomavirus is a high-risk human papillomavirus.

14. The method of claim 10 , wherein the human papillomavirus is a high-risk human papillomavirus.

15. The method of claim 11 , wherein the human papillomavirus is a high-risk human papillomavirus.

16. The method of claim 12 , wherein the human papillomavirus is a high-risk human papillomavirus.

17. The method of claim 13 , wherein the human papillomavirus is selected from the group consisting of HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

18. The method of claim 14 , wherein the human papillomavirus is selected from the group consisting of HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

19. The method of claim 15 , wherein the human papillomavirus is selected from the group consisting of HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

20. The method of claim 16 , wherein the human papillomavirus is selected from the group consisting of HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

21. The method of claim 9 , wherein the host is a human.

22. The method of claim 10 , wherein the host is a human.

23. The method of claim 11 , wherein the host is a human.

24. The method of claim 12 , wherein the host is a human.

25. A method for treatment of a host infected with human papillomavirus comprising administering to said host in need thereof an effective amount of a compound of the structure:

or its pharmaceutically acceptable salt.

26. A compound selected from the group consisting of:

Assignees

• Univ California

Inventors

• Hostetler Karl Y
• Beadle James R
• Valiaeva Nadejda

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title

• C07F9/40 Primary

  Esters thereof · CPC title

• C07F9/6571

  having phosphorus and oxygen atoms as the only ring hetero atoms · CPC title

• C07F9/6561

  containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings · CPC title